Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39


Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registry.

Egeberg A, Iversen L, Gniadecki R, Hvid L, Dam TN, Bryld LE, Skov L.

J Eur Acad Dermatol Venereol. 2017 Mar 8. doi: 10.1111/jdv.14200. [Epub ahead of print]


Factors Associated with Receiving Biologics or Classic Systemic Therapy for Moderate-to-Severe Psoriasis: Evidence from the PSONET Registries.

Davila-Seijo P, Garcia-Doval I, Naldi L, Cazzaniga S, Augustin M, Rustenbach SJ, Daudén E, Dam TN, Baker C, Spuls PI, Stern RS, Cohen AD.

Acta Derm Venereol. 2017 Apr 6;97(4):516-518. doi: 10.2340/00015555-2586.


The Danish Nonmelanoma Skin Cancer Dermatology Database.

Lamberg AL, Sølvsten H, Lei U, Vinding GR, Stender IM, Jemec GB, Vestergaard T, Thormann H, Hædersdal M, Dam TN, Olesen AB.

Clin Epidemiol. 2016 Oct 25;8:633-636. eCollection 2016. Review.


Exploring Valrubicin's Effect on Propionibacterium Acnes-Induced Skin Inflammation in Vitro and in Vivo.

Rottboell L, de Foenss S, Thomsen K, Christiansen H, Andersen SM, Dam TN, Rosada C, Stenderup K.

Dermatol Reports. 2015 Dec 17;7(3):6246. doi: 10.4081/dr.2015.6246. eCollection 2015 Dec 3.


AZ17: a new bispecific drug targeting IL-6 and IL-23 with potential clinical use--improves psoriasis in a human xenograft transplantation model.

Stenderup K, Rosada C, Shanebeck K, Brady W, Van Brunt MP, King G, Marelli M, Slagle P, Xu H, Nairn NW, Johnson J, Wang AA, Li G, Thornton KC, Dam TN, Grabstein KH.

Protein Eng Des Sel. 2015 Oct;28(10):467-80. doi: 10.1093/protein/gzv034. Epub 2015 Aug 12.


Debio 0932, a new oral Hsp90 inhibitor, alleviates psoriasis in a xenograft transplantation model.

Stenderup K, Rosada C, Gavillet B, Vuagniaux G, Dam TN.

Acta Derm Venereol. 2014 Nov;94(6):672-6. doi: 10.2340/00015555-1838.


Valrubicin activates PKCa in keratinocytes: a conceivable mode of action in treating hyper-proliferative skin diseases.

Laugesen IG, Hauge E, Andersen SM, Stenderup K, de Darkó E, Dam TN, Rosada C.

J Drugs Dermatol. 2013 Oct;12(10):1156-62.


Systemic psoriasis therapy shows high between-country variation: a sign of unwarranted variation? Cross-sectional analysis of baseline data from the PSONET registries.

Garcia-Doval I, Rustenbach SJ, Stern R, Dam TN, Cohen AD, Baker C, Spuls PI, Naldi L; Psonet Network..

Br J Dermatol. 2013 Sep;169(3):710-4. doi: 10.1111/bjd.12344. No abstract available.


Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study.

Ahlehoff O, Skov L, Gislason G, Lindhardsen J, Kristensen SL, Iversen L, Lasthein S, Gniadecki R, Dam TN, Torp-Pedersen C, Hansen PR.

J Intern Med. 2013 Feb;273(2):197-204. doi: 10.1111/j.1365-2796.2012.02593.x. Epub 2012 Oct 11.


Challenges for synthesising data in a network of registries for systemic psoriasis therapies.

Ormerod AD, Augustin M, Baker C, Chosidow O, Cohen AD, Dam TN, Garcia-Doval I, Lecluse LL, Schmitt-Egenolf M, Spuls PI, Watson KD, Naldi L.

Dermatology. 2012;224(3):236-43. doi: 10.1159/000338572. Epub 2012 Jun 1.


Pharmacological undertreatment of coronary risk factors in patients with psoriasis: observational study of the Danish nationwide registries.

Ahlehoff O, Skov L, Gislason G, Lindhardsen J, Kristensen SL, Iversen L, Lasthein S, Gniadecki R, Dam TN, Torp-Pedersen C, Hansen PR.

PLoS One. 2012;7(4):e36342. doi: 10.1371/journal.pone.0036342. Epub 2012 Apr 30.


Topical valrubicin application reduces skin inflammation in murine models.

Hauge E, Christiansen H, Rosada C, de Darkó E, Dam TN, Stenderup K.

Br J Dermatol. 2012 Aug;167(2):288-95. doi: 10.1111/j.1365-2133.2012.10964.x. Epub 2012 Jul 5.


Stereological estimation of epidermal volumes and dermo-epidermal surface area in normal skin.

Kamp S, Balkert LS, Stenderup K, Rosada C, Pakkenberg B, Kemp K, Jemec GB, Dam TN.

Dermatology. 2011;223(2):131-9. doi: 10.1159/000330737. Epub 2011 Sep 13.


Teledermatology with an integrated nurse-led clinic on the Faroe Islands--7 years' experience.

Bryld LE, Heidenheim M, Dam TN, Dufour N, Vang E, Agner T, Jemec GB.

J Eur Acad Dermatol Venereol. 2011 Aug;25(8):987-90. doi: 10.1111/j.1468-3083.2010.03884.x. Epub 2010 Nov 4.


Resolution of psoriasis by a leukocyte-targeting bacterial protein in a humanized mouse model.

Stenderup K, Rosada C, Dam TN, Salerno E, Belinka BA, Kachlany SC.

J Invest Dermatol. 2011 Oct;131(10):2033-9. doi: 10.1038/jid.2011.161. Epub 2011 Jun 9.


Statistical evaluation and experimental design of a psoriasis xenograft transplantation model treated with cyclosporin A.

Stenderup K, Rosada C, Alifrangis L, Andersen S, Dam TN.

Exp Dermatol. 2011 May;20(5):441-4. doi: 10.1111/j.1600-0625.2011.01251.x. Epub 2011 Mar 22.


Targeting of human interleukin-12B by small hairpin RNAs in xenografted psoriatic skin.

Bak RO, Stenderup K, Rosada C, Petersen LB, Moldt B, Dagnæs-Hansen F, Jakobsen M, Kamp S, Jensen TG, Dam TN, Mikkelsen JG.

BMC Dermatol. 2011 Feb 27;11:5. doi: 10.1186/1471-5945-11-5.


Hidradenitis suppurativa: a disease of the absent sebaceous gland? Sebaceous gland number and volume are significantly reduced in uninvolved hair follicles from patients with hidradenitis suppurativa.

Kamp S, Fiehn AM, Stenderup K, Rosada C, Pakkenberg B, Kemp K, Dam TN, Jemec GB.

Br J Dermatol. 2011 May;164(5):1017-22. doi: 10.1111/j.1365-2133.2011.10224.x.


Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.

Gniadecki R, Kragballe K, Dam TN, Skov L.

Br J Dermatol. 2011 May;164(5):1091-6. doi: 10.1111/j.1365-2133.2011.10213.x. Epub 2011 Apr 11.


Topical application of valrubicin has a beneficial effect on developing skin tumors.

Andersen SM, Rosada C, Dagnaes-Hansen F, Laugesen IG, de Darkó E, Dam TN, Stenderup K.

Carcinogenesis. 2010 Aug;31(8):1483-90. doi: 10.1093/carcin/bgq122. Epub 2010 Jun 16.


Supplemental Content

Support Center